A critical analysis of the use of p53 as a marker for management of bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 75-82

  Olumi, Aria F ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

BLADDER CANCER; CARCINOGENESIS; CHEMOSENSITIVITY; DISEASE MARKER; HIGH RISK PATIENT; HUMAN; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033960423     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70236-6     Document Type: Article

References (74)

1. H.J. Brady G. Gil-Gomez Bax: The pro-apoptotic Bcl-2 family member, Bax Int J Biochem Cell Biol 30 1998 647 650
2. C. Cordon-Cardo Z.F. Zhang G. Dalbagni Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors Cancer Res 57 1997 1217 1221
3. R.J. Cote M.D. Dunn S.J. Chatterjee Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53 Cancer Res 58 1998 1090 1094
4. R.J. Cote D. Esrig S. Groshen p53 and treatment of bladder cancer Nature 385 1997 123 125
5. H.F. Ding D.E. Fisher Mechanisms of p53-mediated apoptosis Crit Rev Oncog 9 1998 83 98
6. W.S. el-Deiry p21/p53, cellular growth control and genomic integrity Curr Top Microbiol Immunol 227 1998 121 137
7. W.S. el-Deiry Regulation of p53 downstream genes Semin Cancer Biol 8 1998 345 357
8. D. Esrig D. Elmajian S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259 1264
9. D. Esrig J.A. Freeman J.P. Stein Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder Semin Urol Oncol 15 1997 154 160
10. D. Esrig C.H. Spruck P.W. Nichols p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer Am J Pathol 143 1993 1389 1397
11. S.H. Glick L.P. Howell R.W. White Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder J Urol 155 1996 1754 1757
12. G.D. Grossfeld D.A. Ginsberg J.P. Stein Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression J Natl Cancer Inst 89 1997 219 227
13. H.B. Grossman M. Liebert M. Antelo p53 and RB expression predict progression in T1 bladder cancer Clin Cancer Res 4 1998 829 834
14. C.C. Harris p53: At the crossroads of molecular carcinogenesis and molecular epidemiology J Investig Dermatol Symp Proc 1 1996 115 118
15. C.C. Harris Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies J Natl Cancer Inst 88 1996 1442 1455
16. Y. Haupt R. Maya A. Kazaz Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
17. H.W. Herr D.F. Bajorin H.I. Scher Can p53 help select patients with invasive bladder cancer for bladder preservation? [see comments] J Urol 161 1999 20 22 discussion, 22–23
18. H.W. Herr V.P. Laudone R.A. Badalament Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer J Clin Oncol 6 1988 1450 1455
19. H.W. Herr D.D. Wartinger W.R. Fair Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year followup J Urol 147 1992 1020 1023
20. R. Honda H. Tanaka H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett 420 1997 25 27
21. R.H. Hruban P. van der Riet Y.S. Erozan Brief report: Molecular biology and the early detection of carcinoma of the bladder—the case of Hubert H. Humphrey N Engl J Med 330 1994 1276 1278
22. K. Ick M. Schultz P. Stout Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment Urology 49 1997 541 546 discussion, 546–547
23. S. Jahnson M.G. Karlsson Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy J Urol 160 1998 1291 1296
24. W.G. Kaelin Jr The emerging p53 gene family J Natl Cancer Inst 91 1999 594 598
25. M. Kaghad H. Bonnet A. Yang Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 90 1997 809 819
26. Y. Kakehi E. Ozdemir T. Habuchi Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas Jpn J Cancer Res 89 1998 214 220
27. T. Kamijo J.D. Weber G. Zambetti Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc Natl Acad Sci U S A 95 1998 8292 8297
28. L.R. Kavoussi R.J. Torrence D.P. Gillen Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors J Urol 139 1988 935 940
29. K.W. Kinzler B. Vogelstein Landscaping the cancer terrain Science 280 1998 1036 1037
30. E.A. Klein A. Rogatko H.W. Herr Management of local bacillus Calmette-Guerin failures in superficial bladder cancer J Urol 147 1992 601 605
31. P. Korkolopoulou P. Christodoulou P. Kapralos The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer Pathol Res Pract 193 1997 767 775
32. S. Kovalev N. Marchenko S. Swendeman Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines Cell Growth Differ 9 1998 897 903
33. M.H. Kubbutat S.N. Jones K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
34. L. Lacombe G. Dalbagni Z.F. Zhang Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome J Clin Oncol 14 1996 2646 2652
35. S.H. Landis T. Murray S. Bolden Cancer statistics, 1999 [see comments] CA Cancer J Clin 49 1999 8 31
36. T. Lebret V. Becette M. Barbagelatta Correlation between p53 overexpression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with TIG3 bladder cancer J Urol 159 1998 788 791
37. S.W. Lowe H.E. Ruley T. Jacks p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
38. M. Mai H. Huang C. Reed Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions Genomics 51 1998 359 363
39. V.W. Merz D. Marth R. Kraft Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder Br J Urol 75 1995 180 184
40. S. Nomoto N. Haruki M. Kondo Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers Cancer Res 58 1998 1380 1383
41. A.F. Olumi Y.C. Tsai P.W. Nichols Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder Cancer Res 50 1990 7081 7083
42. M. Osada M. Ohba C. Kawahara Cloning and functional analysis of human p51, which structurally and functionally resembles p53 [see comments] [published erratum appears in Nat Med 4:982, 1998] Nat Med 4 1998 839 843
43. I. Osen S.D. Fossa B. Majak Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: An immunohistochemical study Br J Urol 81 1998 862 869
44. H. Ovesen T. Horn K. Steven Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation J Urol 157 1997 1655 1659
45. H. Ovesen A.L. Poulsen K. Steven Intravesical bacillus Calmette-Guerin with the Danish strain for treatment of carcinoma in situ of the bladder Br J Urol 72 1993 744 748
46. F. Pages T.A. Flam A. Vieillefond p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors J Urol 159 1998 1079 1084
47. C. Pfister J.M. Flaman F. Dunet p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy J Urol 162 1999 69 73
48. J. Pomerantz N. Schreiber-Agus N.J. Liegeois The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723
49. C. Prives P.A. Hall The p53 pathway J Pathol 187 1999 112 126
50. M.P. Raitanen T.L. Tammela M. Kallioinen p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer J Urol 157 1997 1250 1253
51. E. Righi G. Rossi G. Ferrari Dose p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol 17 1997 436 439
52. A.S. Sarkis D.F. Bajorin V.E. Reuter Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol 13 1995 1384 1390
53. A.S. Sarkis G. Dalbagni C. Cordon-Cardo Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression J Natl Cancer Inst 85 1993 53 59
54. H. Schmale C. Bamberger A novel protein with strong homology to the tumor suppressor p53 Oncogene 15 1997 1363 1367
55. L. Sengelov T. Horn K. Steven p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer J Cancer Res Clin Oncol 123 1997 565 570
56. M. Senoo N. Seki M. Ohira A second p53-related protein, p73L, with high homology to p73 [published erratum appears in Biochem Biophys Res Commun 250:536, 1998] Biochem Biophys Res Commun 248 1998 603 607
57. H. Shiina M. Igawa K. Shigeno Clinical significance of mdm2 and p53 expression in bladder cancer: A comparison with cell proliferation and apoptosis Oncology 56 1999 239 247
58. D. Sidransky A. Von Eschenbach Y.C. Tsai Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706 709
59. L.L. Siu D. Banerjee R.J. Khurana The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma Clin Cancer Res 4 1998 559 565
60. C.H. Spruck P.F. Ohneseit M. Gonzalez-Zulueta Two molecular pathways to transitional cell carcinoma of the bladder Cancer Res 54 1994 784 788
61. J.P. Stein D.A. Ginsberg G.D. Grossfeld Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer [see comments] J Natl Cancer Inst 90 1998 1072 1079
62. F.J. Stott S. Bates M.C. James The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2 Embo J 17 1998 5001 5014
63. K. Sugano M. Tsutsumi Y. Nakashima Diagnosis of bladder cancer by analysis of the allelic loss of the p53 gene in urine samples using blunt-end single-strand conformation polymorphism Int J Cancer 74 1997 403 406
64. H. Takahashi S. Ichimiya Y. Nimura Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma Cancer Res 58 1998 2076 2077
65. B. Tetu Y. Fradet P. Allard Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer J Urol 155 1996 1784 1788
66. B. Trink K. Okami L. Wu A new human p53 homologue [letter] [see comments] [published erratum appears in Nat Med 1998 Sep;4(9):982] Nat Med 4 1998 747 748
67. V. Vatne H. Maartmann-Moe J. Hoestmark The prognostic value of p53 in superficially infiltrating transitional cell carcinoma Scand J Urol Nephrol 29 1995 491 495
68. J.A. Vet P.P. Bringuier P.J. Poddighe p53 mutations have no additional prognostic value over stage in bladder cancer Br J Cancer 70 1994 496 500
69. J.A. Vet J.A. Witjes S.A. Marras Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer Clin Cancer Res 2 1996 1055 1061
70. T. Waldman C. Lengauer K.W. Kinzler Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 [see comments] Nature 381 1996 713 716
71. C.S. Wu A. Pollack B. Czerniak Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy Urology 47 1996 305 310
72. A. Yang M. Kaghad Y. Wang p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol Cell 2 1998 305 316
73. J. Zha H. Harada E. Yang Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 87 1996 619 628
74. Y. Zhang Y. Xiong W.G. Yarbrough ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways Cell 92 1998 725 734